CLN-049

A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Near Add Your Location

Sorting 9 by

Center of Excellence

Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Accepting patients

Center of Excellence

Duke Cancer Center
Duke University Medical Center
Durham, NC
  • Accepting patients

Center of Excellence

Winship Cancer Institute
Emory University
Atlanta, GA
  • Accepting patients

Center of Excellence

New York University Langone Medical Center
Laura and Isaac Perlmutter Cancer Center
New York, NY
  • Accepting patients

Center of Excellence

MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients

Center of Excellence

Sylvester Comprehensive Cancer Center (Main)
University of Miami Health System
Miami, FL
  • Accepting patients

Center of Excellence

University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
  • Accepting patients

Center of Excellence

Roswell Park Cancer Institute
Buffalo, NY
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.